Imagine your company has just developed a new implantable device. It passes all the mechanical and performance tests, like strength, durability, and functionality, which are flawless. But when you submit it for regulatory approval, the application fails. Why? Because the material triggers harmful biological reactions inside the body.
On this page
This isn’t just a regulatory hiccup. It poses a significant risk to patients and represents a costly setback for manufacturers. Many companies underestimate the importance of biological evaluation until the final stages of development, only to face delays, rework, or even recalls.
This is where ISO 10993 steps in. It’s the internationally recognised framework for assessing the biocompatibility of medical devices, making sure materials are safe and won’t harm patients.
"Think of it as the safety filter every medical device must pass through before it reaches a patient. Done right, it saves time, builds trust, and ensures that innovations in healthcare don’t backfire."
Whether you’re aiming for FDA clearance in the U.S., CE marking in Europe, or TGA approval in Australia, ISO 10993 provides the roadmap.
Helpful Read: ISO 11607 Your Practical Guide to Ensuring Sterile, Safe, and Compliant Medical Packaging
1. Why ISO 10993 Matters
At its core, ISO 10993 exists for one reason: to protect patients. Any device that touches the human body, from surgical instruments to dental implants, carries biological risks. The standard helps companies evaluate and minimise these risks before the product is released.
Here’s why it matters so much for your business:
1.1 Protecting Patient Safety
Every material can potentially trigger unwanted biological effects, from mild skin irritation to systemic toxicity or even cancer. ISO 10993 forces manufacturers to ask: What happens when this device touches or stays inside the human body?
For example, a catheter manufacturer must ensure that the plastic tubing doesn’t leach harmful chemicals into the bloodstream. Without ISO 10993, these risks might go unnoticed until patients are harmed.
1.2 Required by Regulators Worldwide
ISO 10993 isn’t optional. It’s embedded in regulatory frameworks across the globe.
- FDA (U.S.) – biocompatibility data aligned with ISO 10993 is mandatory for 510(k) and PMA submissions.
- EU MDR (Europe) – requires proof of biological safety for CE marking.
- TGA (Australia) and many others reference it directly.
If your device is meant for international markets, compliance is non-negotiable.
1.3 Supporting Market Approvals
Biological evaluation is a gatekeeper for approvals. Even if your device meets mechanical and electrical requirements, you won’t get market clearance without demonstrating biocompatibility. ISO 10993 streamlines this by providing a recognised framework that regulators trust.
1.4 Reducing Legal and Reputational Risks
History shows that recalls due to material safety issues are devastating, financially and reputationally. Following ISO 10993 minimises this risk, protecting both patients and your brand. Hospitals and procurement teams also prefer suppliers with proven biocompatibility processes.
1.5 Building a Strong Business Case
Planning a biological evaluation early in design saves time and cost.
- Proactive companies integrate ISO 10993 assessments from the start and sail smoothly through approvals.
- Reactive companies wait until the end, only to discover they need new tests, new materials, or worse, a redesign.
In short, ISO 10993 isn’t just about compliance. It’s about being safe, trusted, and faster to market.
2. Do You Need ISO 10993? A Practical Checklist
Not every medical product needs the full weight of ISO 10993 testing, but many do, often more than manufacturers initially expect. The standard applies broadly to any device that has direct or indirect contact with the human body.
The key is to ask yourself some straightforward questions. If you answer “yes” to any of these, ISO 10993 almost certainly applies to you:
2.1 Does your device contact the human body?
This could be as simple as a wound dressing that touches the skin, or as complex as a heart valve that sits inside the body permanently. If there’s any form of skin, blood, tissue, or bone contact, a biological evaluation is essential.
2.2 What is the duration of contact?
ISO 10993 classifies devices based on how long they’re in contact with the body:
- Limited exposure: up to 24 hours (e.g., surgical gloves, catheters used during surgery).
- Prolonged exposure: 24 hours to 30 days (e.g., infusion pumps, temporary implants).
- Permanent contact: more than 30 days (e.g., pacemakers, artificial joints).
The longer the contact, the greater the risk — and the deeper the evaluation required.
2.3 Are you using novel materials or coatings?
If your device introduces new polymers, coatings, adhesives, or nanomaterials that haven’t been widely used in medical applications, regulators will expect detailed proof of safety. Even if the base material has a history of safe use, a new additive or surface treatment can change everything.
2.4 Has your manufacturing or sterilisation process changed?
Changes in sterilisation (e.g., switching from ethylene oxide to gamma radiation) or manufacturing methods (e.g., new chemical additives, lubricants, or colourants) can introduce new biological risks. ISO 10993 requires you to re-evaluate safety whenever such changes occur.
2.5 Are you preparing for CE marking or FDA clearance?
Both the EU MDR and the FDA make ISO 10993 evaluation a core submission requirement. If you’re planning to access regulated markets, you can’t skip it.
3. Key Components of ISO 10993
ISO 10993 is not a single laboratory test. It’s a comprehensive framework that guides manufacturers through understanding, evaluating, and proving the biological safety of their devices.
This standard encourages a logical sequence: first analyse your materials, then assess the risks, and finally, perform targeted tests where needed.
3.1 Risk-Based Approach
One of the core strengths of ISO 10993 is that it doesn’t force a one-size-fits-all checklist. Instead, it recognises that every device is different. A skin-contact wound dressing will not face the same risks as a permanent hip implant.
The standard requires you to evaluate the type of body contact and its duration, then tailor your testing strategy accordingly. This avoids wasted resources on unnecessary tests and ensures the focus stays on real risks.
3.2 Material Characterisation
Before running biological tests, manufacturers need to know exactly what their device is made of. This step is called material characterisation. It involves studying the chemical composition of the device, identifying potential leachables, and considering residuals from manufacturing or sterilisation.
For example, even a trace of a cleaning solvent left in the product can affect patient safety. Material characterisation often provides enough evidence to reduce or even eliminate the need for certain animal studies.
3.3 Biocompatibility Testing Categories
When testing is required, ISO 10993 covers a wide range of biological effects. These include cytotoxicity (whether the material harms cells), sensitisation (the risk of allergic reactions), irritation or local reactivity, systemic toxicity, and, for higher-risk devices, more advanced studies such as genotoxicity, carcinogenicity, reproductive toxicity, and implantation. The combination of tests depends on how and where the device is used.
3.4 Biological Evaluation Plan and Report
ISO 10993 expects manufacturers to document their thinking. Before testing, a Biological Evaluation Plan (BEP) explains the risks identified, the strategy for addressing them, and the justification for selected tests.
After testing, a Biological Evaluation Report (BER) ties everything together, presenting data, analysis, and conclusions in a way regulators can rely on. This documentation is as important as the test results themselves.
3.5 Contact and Duration Classification
Finally, the standard provides a classification system based on body contact and exposure time. Devices are grouped as surface, external communicating, or implant, and then further classified as limited (up to 24 hours), prolonged (24 hours to 30 days), or permanent (beyond 30 days). This classification drives which biological endpoints must be considered during evaluation.
Recommended Read: ISO 15378: The Essential Guide to Ensuring Quality in Primary Packaging for Medicinal Products
4. Steps to Align with ISO 10993 (Implementation Roadmap)
Turning ISO 10993 into practice requires a structured roadmap. Instead of rushing straight into laboratory tests, the standard encourages you to follow a logical flow from design through post-market monitoring. Here’s how to approach it step by step.
Step 1: Screen Materials During Design
The process starts early. Choosing the wrong material can derail your project later, so screening for safety upfront is crucial.
For example, if a polymer is known to leach harmful chemicals, it’s easier to replace it at the design stage than after regulatory submission.
Step 2: Conduct Chemical Characterisation
ISO 10993-18 requires you to analyse the chemical composition of your device. This step identifies extractables and leachables that may migrate into the body.
Think of it as building the foundation for everything that follows; without this data, risk assessment isn’t possible.
Step 3: Assess Toxicological Risk
Once you know what substances could be present, ISO 10993-17 guides you in evaluating whether they pose an actual risk to patients. This is where science meets safety: not every detected substance is dangerous, but every potential hazard must be considered.
Step 4: Select Relevant Biocompatibility Tests
With risks identified, you can now determine which biological endpoints need testing. A wound dressing may only need irritation studies, while a permanent implant might require long-term systemic toxicity and implantation trials.
Regulators expect clear justification for the tests you choose and the ones you decide to skip.
Step 5: Perform Testing in Accredited Labs
Biocompatibility testing must be performed in laboratories accredited to Good Laboratory Practice (GLP). Results from non-accredited facilities won’t carry weight with regulators.
Choosing the right lab partner is therefore a business decision as much as a compliance one.
Step 6: Compile the Biological Evaluation Report (BER)
Testing alone isn’t enough. Regulators want to see a clear narrative explaining how you identified risks, which data support safety, and why the device is acceptable for patient use. The BER ties everything together into a single, credible document.
Step 7: Monitor and Update Post-Market
Biological evaluation doesn’t stop at product launch. If you change your materials, coatings, suppliers, or sterilisation method, ISO 10993 requires you to revisit the evaluation. Post-market surveillance also helps confirm that real-world use matches your safety expectations.
5. Challenges in Implementing ISO 10993
Even with a clear roadmap, aligning with ISO 10993 is rarely straightforward. Many manufacturers run into the same barriers from misinterpreting the risk-based approach to underestimating costs. Here are the most common challenges and how to tackle them.
5.1 Misinterpreting the Risk-Based Approach
One of the biggest mistakes companies make is assuming ISO 10993 requires a full battery of tests for every device. In reality, the standard expects you to tailor the evaluation to the risk profile.
Running unnecessary tests wastes money and time, while skipping essential ones can lead to rejection by regulators. The practical advice? Build a strong Biological Evaluation Plan (BEP) early and have it reviewed by an experienced consultant or toxicologist.
5.2 Using Outdated or Irrelevant Data
Reusing old test results can save resources, but only if the data still applies. If the material, supplier, or manufacturing method has changed, regulators are likely to reject outdated evidence.
Always confirm that historical data is still relevant, and document the justification clearly in your Biological Evaluation Report (BER).
5.3 Leaving Evaluation Until the End
Too many companies treat biological evaluation as a “final hurdle” rather than part of design. The danger is that problems surface when it’s already too late to change materials or manufacturing processes without major disruption.
The better approach is to integrate ISO 10993 from the earliest design phases so safety is built in, not bolted on.
5.4 Overlooking Novel Materials
New technologies like nanomaterials, bioresorbable polymers, or surface coatings can behave unpredictably in the body. Regulators will scrutinise them more heavily. If your device involves novel materials, don’t rely on generic safety assumptions. Engage toxicology experts and prepare for deeper testing requirements.
5.5 Managing Costs of Testing
Biocompatibility testing can be expensive, especially if multiple long-term studies are needed. The costs escalate further if tests need to be repeated due to poor planning or lab errors.
To control expenses, prioritise a risk-driven strategy, start with chemical characterisation, reuse existing data where possible, and only commission the tests that are truly required. Outsourcing to experienced consultants or CROs can also reduce wasted cycles.
6. Additional Considerations
Meeting the technical requirements of ISO 10993 is only part of the story. Long-term success depends on how well the biological evaluation is integrated into your overall quality and compliance system.
These additional factors often separate companies that simply achieve compliance from those that build lasting trust and efficiency.
6.1 Integration with ISO 14971
ISO 10993 doesn’t stand alone. It’s closely tied to ISO 14971, the standard for risk management of medical devices. Biological risks should be captured, assessed, and controlled alongside all other product risks.
Treating them in isolation can lead to gaps that regulators will quickly spot. A well-integrated risk file demonstrates that you’ve considered patient safety from every angle.
6.2 Navigating Regulatory Variations
Although ISO 10993 is globally recognised, regulators interpret it differently. The FDA often expects more detailed toxicological justifications, while the EU MDR emphasises lifecycle evaluation and clinical evidence.
If you’re targeting multiple markets, plan your evaluation strategy with these variations in mind. Aligning early with consultants familiar with regional differences can save months of back-and-forth during submissions.
6.3 Reducing Reliance on Animal Testing
There’s growing pressure worldwide to minimise animal studies. ISO 10993 reflects this trend by encouraging the use of in vitro methods and chemical characterisation wherever possible.
Companies that adopt modern approaches not only save costs but also demonstrate ethical responsibility, a factor that increasingly matters to regulators and the public.
6.4 Training and Staff Awareness
Even the best strategy fails if your team doesn’t understand it. Everyone involved, from design engineers to quality managers, should have at least a working knowledge of what ISO 10993 requires.
Training helps avoid mistakes like selecting unsuitable materials or misclassifying device contact types.
6.5 Choosing the Right Partners
Finally, success depends heavily on who you work with. Not all laboratories or consultants are equal. Accredited labs with Good Laboratory Practice (GLP) compliance are non-negotiable.
Beyond that, working with experienced consultants can help you interpret requirements, design efficient testing strategies, and avoid common pitfalls. This is where CertBetter adds value by connecting you with verified experts who specialise in ISO 10993 compliance.
7. FAQs: Common Questions About ISO 10993
Q1: Is ISO 10993 mandatory for all medical devices?
If your device has any direct or indirect contact with the human body, ISO 10993 applies. This includes products that touch skin, blood, tissue, or bone, even briefly. Non-contact devices like external monitors may not need it.
Q2: How long does biological testing take?
It depends on the device and the required studies. Basic tests like cytotoxicity or irritation can take a few weeks, while long-term implantation or carcinogenicity studies may last months. Building in extra time during product development is essential.
Q3: Can we avoid animal testing?
In many cases, yes. ISO 10993 encourages using existing data, chemical characterisation, and in vitro alternatives before commissioning animal studies. Regulators prefer this approach, provided the evidence is robust.
Q4: Do we need a new evaluation if we change sterilisation methods?
Absolutely. Sterilisation can leave behind chemical residues or alter material properties. Switching from ethylene oxide to gamma radiation, for example, may introduce new risks that require re-evaluation under ISO 10993.
Q5: Who performs ISO 10993 testing?
Testing is carried out by accredited laboratories that comply with Good Laboratory Practice (GLP). Working with GLP labs ensures your data is credible and acceptable to regulators.
Q6: What if our device fails a test?
Failure doesn’t always mean the end. In some cases, you may need to adjust materials, change coatings, or refine manufacturing processes. With the right strategy, issues can often be resolved without scrapping the entire product.
8. Where to Download ISO 10993 PDF?
To ensure you’re working with the most accurate and up-to-date version of ISO 10993, always purchase it directly from official sources such as the ISO Store or your national standards body (for example, BSI in the UK, ANSI in the US, or Standards Australia). Unofficial or free copies circulating online are often outdated, incomplete, or unreliable, and using them can lead to compliance issues or even rejection by regulators.
9. Conclusion: Why ISO 10993 Is Essential for Safe and Compliant Devices
ISO 10993 is more than a technical requirement. It’s the assurance that medical devices will not harm the people they’re designed to help. By guiding manufacturers through risk assessment, material characterisation, and targeted biological testing, it builds a foundation of safety and trust.
Companies that take ISO 10993 seriously and integrate it early into design and development not only protect patients but also save time, reduce costs, and speed up market approvals. Those who treat it as a box-ticking exercise often face delays, re-testing, or even product recalls.
On CertBetter, you can connect with verified consultants, testing laboratories, and certification bodies who specialise in ISO 10993. Whether you’re a startup bringing your first device to market or a global manufacturer refining compliance, CertBetter helps you find the right experts to guide your project with confidence.
